Search results
Results From The WOW.Com Content Network
[9] [a] It also requires the Department of Health and Human Services to investigate the medical utility of cannabis and barriers that exist to conducting research, and requires the Attorney General to conduct an annual review to ensure that cannabis is being adequately produced for research purposes.
Cannabis as illustrated in Köhler's Book of Medicinal Plants, 1897. Overall, research into the health effects of medical cannabis has been of low quality and it is not clear whether it is a useful treatment for any condition, or whether harms outweigh any benefit. [18] There is no consistent evidence that it helps with chronic pain and muscle ...
Hemp protein is rich in essential amino acids, containing, in sufficient quantities, all essential amino acids required by humans except lysine, which appears at lower than recommended levels for infants aged up to five years old according to Food and agricultural organization (FOA) standards; still, the overall nutritive value of hemp protein remains relatively good, as sulfur-containing ...
Right now, medical marijuana is commonly used to treat nausea, chronic pain, glaucoma and a range of other issues. But that might not be all that the drug can do. Several studies have uncovered ...
A 2021 review published in Frontiers in Psychiatry notes that people with serious mental health conditions use cannabis “at rates much higher than the general population.” The lifetime ...
Due to increasing public awareness of the medical benefits of cannabis, and in anticipation of forthcoming changes to federal policy, a number of states passed laws in the late 1970s and early 1980s addressing the medical use of cannabis. [13] New Mexico was the first to do so in 1978, and by the end of 1982 over thirty states had followed suit ...
A 2015 review found that the use of high CBD-to-THC strains of cannabis showed significantly fewer positive symptoms, such as delusions and hallucinations, better cognitive function and both lower risk for developing psychosis, as well as a later age of onset of the illness, compared to cannabis with low CBD-to-THC ratios.
Nabiximols (brand name Sativex), an oromucosal spray made of a complex botanical mixture containing cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and additional cannabinoid and non-cannabinoid constituents from cannabis sativa plants, was approved by Health Canada in 2005, to treat central neuropathic pain in multiple sclerosis, and in ...